title: Rhegmatogenous retinal detachment following treatment for retinoblastoma.
abstract: OBJECTIVE
  To elucidate characteristics of rhegmatogenous retinal detachment that developed in children who underwent treatment for retinoblastoma and to analyze the outcome following vitreoretinal surgery in such clinical settings.
  
  
  METHODS
  This was a retrospective case series of 9 eyes of 9 patients who underwent vitreoretinal surgery for tumor control and retinal reattachment.
  
  
  RESULTS
  At the time of diagnosis of rhegmatogenous retinal detachment, retinoblastoma was regressed in 6 eyes (67%). The retinal detachment involved less than two quadrants in 7 eyes (78%) and was caused by an atrophic break in 7 eyes. Seven eyes underwent a non-drainage scleral buckling procedure. Three eyes underwent vitreous surgery; in 2 of these eyes, tumor excision along with retinectomy using melphalan infusion was performed and eventually silicone oil tamponade was used. Retinal reattachment was achieved in all eyes with eventual tumor control in 7 eyes. The median follow-up after retinal reattachment surgery was 24 months.
  
  
  CONCLUSIONS
  Rhegmatogenous retinal detachment in treated eyes with retinoblastoma is usually caused by an atrophic retinal break. Retinal detachment can be repaired successfully in most eyes.
authors.affiliation: Vision Research Foundation, Chennai, Tamil Nadu, India.
authors.forename: Swakshyar
authors.initials: S
authors.lastname: Saumya Pal
authors.forename: Lingam
authors.initials: L
authors.lastname: Gopal
authors.forename: Vikas
authors.initials: V
authors.lastname: Khetan
authors.forename: Amit
authors.initials: A
authors.lastname: Nagpal
authors.forename: Tarun
authors.initials: T
authors.lastname: Sharma
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002675:Child, Preschool; D003131:Combined Modality Therapy; D017679:Cryotherapy; D058450:Endotamponade; D015353:Eye Enucleation; D005260:Female; D006801:Humans; D007223:Infant; D017075:Laser Coagulation; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D009367:Neoplasm Staging; D011183:Postoperative Complications; D011882:Radiotherapy, High-Energy; D012163:Retinal Detachment / Q000175:diagnosis / Q000209:etiology* / Q000601:surgery; D019572:Retinal Neoplasms / Q000473:pathology / Q000628:therapy*; D012167:Retinal Perforations / Q000175:diagnosis / Q000209:etiology / Q000601:surgery; D012175:Retinoblastoma / Q000473:pathology / Q000628:therapy*; D012591:Scleral Buckling; D013997:Time Factors; D016896:Treatment Outcome; D014821:Vitrectomy; D057586:Vitreoretinal Surgery
chemical_list: D000970:Antineoplastic Agents; D008558:Melphalan